• Molecular NameRepaglinide
  • SynonymAG-EE 388 ZW; AG-EE 623 ZW; Repaglinida [INN-Spanish]; repaglinide; Repaglinidum [INN-Latin]
  • Weight452.595
  • Drugbank_IDDB00912
  • ACS_NO135062-02-1
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)5.45
  • pkaN/A
  • LogD (pH=7, predicted)2.33
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-3.63
  • LogSw (predicted, AB/LogsW2.0)0.01
  • Sw (mg/ml) (predicted, ACD/Labs)0.01
  • No.of HBond Donors2
  • No.of HBond Acceptors6
  • No.of Rotatable Bonds10
  • TPSA78.87
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA drug is used for the treatment of type II diabetes.
  • Absorption_value100.0
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability56.0
  • Protein binding97.4
  • Volume of distribution (VD)0.41 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmUndergoes extensive oxidative and conjugative metabolism; CYP3A4 has been implicated in the formation of the major (60% of dose) metabolite.
  • Half life0.8 h
  • ExcretionFecal (90%) and renal (8%)
  • Urinary Excretion0.3~2.6
  • Clerance9.3 ml/min/kg
  • ToxicityLD50 >1 g/kg (rat) (W. Grell)
  • LD50 (rat)N/A
  • LD50 (mouse)N/A